

## The Synthesis of 3-(2'-Hydroxybutyl) isobenzofuran-1 (3H)-one

Guo Xin WANG<sup>1</sup>, Guo Hao XIE<sup>3</sup>, Yuan Liu WU<sup>2,\*</sup>, Xin Fu PAN<sup>1</sup>

<sup>1</sup>Laboratory of Applied Organic Chemistry, Institute of Organic Chemistry, Lanzhou University, Lanzhou, 730000


<sup>2</sup>Institute of Materia Medica, Chinese Academy of Medical Science, Beijing, 100050

<sup>3</sup>Department of Chemistry, Shangrao Normol College, 334001

**Abstract:** The synthesis of 3-(2'-hydroxybutyl) isobenzofuran-1 (3H)-one **1** from phthalic anhydride *via* the intermediate 3-(2'-oxoethyl) isobenzofuran-1 (3H)-one **6** was described.

**Keywords:** Synthesis, 3-(2'-hydroxybutyl) isobenzofuran-1 (3H)-one.

1 (3H)-Isobenzofurans (phthalides) were reported to exhibit a wide range of biological activities. For example, 3-n-butylphthalide (NBP) exhibits antiasthmatic<sup>1</sup>, anticonvulsant<sup>2</sup> activities. Peng and Zhou have studied on the metabolism of NBP in rats<sup>3</sup>. They found that 3-(3'-hydroxybutyl) isobenzofuran-1 (3H)-one, 3-(2'-hydroxybutyl) isobenzofuran-1 (3H)-one **1** and 3-hydroxy-3-butylisobenzofuran-1 (3H)-one were the main metabolites of NBP. The research of their pharmacology is helpful to search for the drugs against cerebral ischemia. Now, we report a route to 3-(2'-hydroxybutyl) isobenzofuran-1 (3H)-one **1** (Figure 1).




Reagents and conditions: a: 1) NaBH<sub>4</sub>/DMF, 0 °C; 2) NBS/ (PhCO<sub>2</sub>)<sub>2</sub>O, CCl<sub>4</sub>; 3) H<sub>2</sub>SO<sub>4</sub>/THF/H<sub>2</sub>O; b: BrCH<sub>2</sub>CH=CH<sub>2</sub>, Sn, THF, 35 °C; c: m-ClC<sub>6</sub>H<sub>4</sub>CO<sub>3</sub>H/CH<sub>2</sub>Cl<sub>2</sub>, 0 °C; d: H<sub>5</sub>IO<sub>6</sub>/H<sub>2</sub>O, 45 °C; e: 1) (C<sub>2</sub>H<sub>5</sub>)<sub>2</sub>Zn/Et<sub>2</sub>O, R.T.; 2) NH<sub>4</sub>Cl

Many methods of the synthesis of **3** have been reported. We synthesized **3** according to Ref.4. Reaction of **3** with allyl bromide in THF at 35 °C in the presence of activated Sn afforded the 3-allylisobenzofuran-1 (3H)-one **4**<sup>5</sup> as a pale yellow oil. Compared with Grignard reaction, this reaction did not require anhydrous conditions and under nitrogen protection and the yield was excellent (95%). **4** was epoxidized with *m*-chloroperoxybenzoic acid (mCPBA) in CH<sub>2</sub>Cl<sub>2</sub> to afford 3-(2', 3'-epoxypropyl)

isobenzofuran-1 (3H)-one **5** as white powder (melted at 64-66 °C) in 90% yield after silica gel chromatography. **5** consists of two diastereoisomers in a ratio of about 3:2 based on <sup>1</sup>HNMR. We propose that the intermolecular hydrogen bonding between **4** and mCPBA results in the diastereoselectivity of reaction (**Figure 2**). Molecular models suggest that the hindrance between Ha and Hc is stronger than that between Ha and Hb.

**Figure 2.**



Reaction of **5** with periodic acid in water at 45 °C afforded 3-(2'-oxoethyl) isobenzofuran-1 (3H)-one **6** as a yellow oil in 90% yield after silica gel chromatography<sup>7</sup>.

We attempted to synthesize **1** *via* reaction of **6** with C<sub>2</sub>H<sub>5</sub>MgBr in Et<sub>2</sub>O at -78 °C, but the products were complicated and the yield of **1** was poor. Finally, we used (C<sub>2</sub>H<sub>5</sub>)<sub>2</sub>Zn instead of C<sub>2</sub>H<sub>5</sub>MgBr. Reaction of **6** with (C<sub>2</sub>H<sub>5</sub>)<sub>2</sub>Zn in Et<sub>2</sub>O at room temperature proceeded smoothly and afforded the desired 3-(2'-hydroxybutyl) isobenzofuran-1 (3H)-one **1** as a yellow oil in 80% yield after silica gel chromatography. **1** consists of two diastereoisomers in a ratio of about 1:1 based on <sup>1</sup>HNMR spectrum<sup>8</sup>. TLC was carried out with different solvent systems, but two diastereoisomers could not be separated by silica gel chromatography. The synthesis of the optical isomers of **1** was.

## References and Notes

1. Y.P. Feng, D.Hu, L.Y.Zhang, *Acta Pharm.Sinica.*, **1995**, 30 (6), 741.
2. S.Y.Yu, S.Q.You, *Acta Pharm. Sinica.*, **1984**, 19 (8), 566.
3. S.H.Peng, T.H.Zhou, *Acta Pharm. Sinica.*, **1997**, 32 (6), 641.
4. C. Donat, R.H. Prager, B. Weber, *Aust. J. Chem.*, **1989**, 42, 787.
5. The spectra of **4**: IR (film, cm<sup>-1</sup>): 1767 (C=O), 1645 (C=C); <sup>1</sup>HNMR (500MHz, CDCl<sub>3</sub>) δ : 2.61-2.65 (1H, m, H1'), 2.71-2.75 (1H, m, H1'), 5.10-5.18 (2H, m, H3'), 5.50 (1H, t, J=6.0, H3), 5.69-5.76 (1H, m, H2'), 7.46 (1H, t, J=6.7, H4), 7.51 (1H, t, J=6.6, H6), 7.65 (1H, J=6.5, H5), 7.86 (1H, d, J=6.7, H7); m/z (EI): 174 (M<sup>+</sup>, 2), 133 (M<sup>+</sup>-41, 100).
6. The spectra of **5**: IR (KBr, cm<sup>-1</sup>): 1759 (COO), 1065 (COC); <sup>1</sup>HNMR (300MHz, CDCl<sub>3</sub>) δ : 2.06 (1H, m, H1'), 2.30 (1H, m, H1'), 2.59, 2.73 (1H, m, H3'), 2.80, 2.89 (1H, m, H3'), 3.04, 3.29 (1H, m, H2'), 5.58 (t, J=6.6, H3), 5.68 (t, J=5.6, H3), 7.48 (1H, t, J=6.6, H4), 7.53 (1H, t, J=6.9, H6), 7.71 (1H, m, H5), 7.92 (1H, d, J=6.9, H7); m/z (EI): 191 (M<sup>+</sup>+1, 4), 173 (M<sup>+</sup>-OH, 4), 160 (M<sup>+</sup>-CH<sub>2</sub>OH+1, 25), 133 (M<sup>+</sup>-CH<sub>2</sub>CHOCH<sub>2</sub>, 100).
7. The spectra of **6**: IR (film, cm<sup>-1</sup>): 1761 (COO), 1726 (CHO); <sup>1</sup>HNMR (500MHz, CDCl<sub>3</sub>) δ : 3.10 (2H, m, H1'), 5.97 (1H, t, J=6.3, H3), 7.49 (1H, d, J=7.8, H4), 7.54 (1H, t, J=7.5, H6), 7.69 (1H, t, J=7.8, H5), 7.91 (1H, d, J=7.8, H7), 9.87 (1H, s, H2'); m/z (EI): 176 (M<sup>+</sup>, 22), 147 (M<sup>+</sup>-CHO, 55), 133 (M<sup>+</sup>-CH<sub>2</sub>CHO, 100).
8. The spectra of **1**: IR (film, cm<sup>-1</sup>): 3460 (OH), 1751 (COO); <sup>1</sup>HNMR (500MHz, CDCl<sub>3</sub>) δ : 0.98 (3H, m, H4'), 1.53-1.73 (2H, m, H3'), 1.95 (1H, m, H1'), 2.15 (1H, m, H1'), 3.95 (0.5H, m, H2'), 4.04 (0.5H, m, H2'), 5.65 (0.5H, dd, J=4.4, 8.5, H3), 5.78 (0.5H, d., J=9.8, H3), 7.45-7.56 (2H, m, H4, H6), 7.68 (1H, m, H5), 7.91 (1H, d, J=7.5, H7); m/z (EI): 207 (M<sup>+</sup>+1, 2), 188 (M<sup>+</sup>-H<sub>2</sub>O, 15), 177 (M<sup>+</sup>-CH<sub>3</sub>CH<sub>2</sub>, 8), 159 (M<sup>+</sup>-CH<sub>3</sub>CH<sub>2</sub>-H<sub>2</sub>O, 32), 146 (M<sup>+</sup>-CH<sub>3</sub>CH<sub>2</sub>CH (OH)-1, 25), 133 (M<sup>+</sup>-CH<sub>3</sub>CH<sub>2</sub>CH (OH) CH<sub>2</sub>, 100).